LoginSignup
Abcellera logo

Abcellera

Stock
Stock
ISIN: CA00288U1066
Ticker: ABCL
CA00288U1066
ABCL

Price

Price

Frequently asked questions

What is Abcellera's market capitalization?

The market capitalization of Abcellera is $803.40M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Abcellera?

Abcellera's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.60. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Abcellera's stock?

Currently, 9 analysts cover Abcellera's stock, with a consensus target price of $15.25. Analyst ratings provide insights into the stock's expected performance.

What is Abcellera's revenue over the trailing twelve months?

Over the trailing twelve months, Abcellera reported a revenue of $32.96M.

What is the EBITDA for Abcellera?

Abcellera's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$219.03M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Abcellera?

Abcellera has a free cash flow of -$197.36M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Abcellera's stock?

The 5-year beta for Abcellera is 0.36. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Abcellera have, and what sector and industry does it belong to?

Abcellera employs approximately 586 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Abcellera's shares?

The free float of Abcellera is 212.66M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $803.40M

5Y beta

 0.36

EPS (TTM)

 -$0.60

Free Float

 212.66M

Revenue (TTM)

 $32.96M

EBITDA (TTM)

 -$219.03M

Free Cashflow (TTM)

 -$197.36M

Pricing

1D span
$2.665$2.828
52W span
$2.335$6.055

Analyst Ratings

The price target is $15.25 and the stock is covered by 9 analysts.

Buy

9

Hold

0

Sell

0

Information

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The Company has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The Company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.

586

Biotechnology & Drugs

Health Care

Identifier

ISIN

CA00288U1066

Primary Ticker

ABCL

Knockouts

Join the conversation
Sign upLogin